Jaguar Animal Health, Inc. (NASDAQ:JAGX) Shares Shorted: Short Interest Down 74.2% in September

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the target of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 84,156 shares, a decline of 74.2% from the September 15th total of 326,132 shares. Approximately 24.5% of the company’s shares are sold short. Based on an average daily volume of 6,733,241 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of Jaguar Animal Health to a “sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Jaguar Animal Health currently has a consensus rating of “Sell”.

Jaguar Animal Health Trading Down 3.1%

NASDAQ JAGX traded down $0.15 on Monday, hitting $4.64. The company’s stock had a trading volume of 480,275 shares, compared to its average volume of 670,957. Jaguar Animal Health has a 52-week low of $2.35 and a 52-week high of $1,260.00. The company has a current ratio of 0.69, a quick ratio of 0.40 and a debt-to-equity ratio of 0.35. The company’s 50-day simple moving average is $9.58 and its 200 day simple moving average is $59.20. The firm has a market cap of $1.58 million, a P/E ratio of -0.00 and a beta of -0.11.

Jaguar Animal Health (NASDAQ:JAGX) last posted its earnings results on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($782.25) by $766.55. The business had revenue of $1.23 million for the quarter, compared to analysts’ expectations of $4.24 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America.

The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S.